江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022 2022-03-09 09:14
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research 2022-02-24 09:41
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052 2022-02-11 09:31
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 2022-01-13 10:46
IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer 2022-01-05 11:49
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 2021-12-23 09:13
Posters Highlighting clinical data of KN026 presented at SABCS 2021 2021-12-09 12:20
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE 2021-11-24 09:35
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC 2021-10-29 09:36
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE 2021-10-21 10:31
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 2021-10-18 10:19
Alphamab Oncology Reports 2021 Interim Results and Business Highlights 2021-08-30 10:51
Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China 2021-08-24 15:08
Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA 2021-06-30 08:55
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 2021-06-07 10:11
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 2021-06-07 10:10
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 2021-06-07 09:53
Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting 2021-05-24 08:54
Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) 2021-05-20 09:34
Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib) 2021-04-29 08:00
1 2 3 4